Newsroom

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors....

PLANO, Texas--(BUSINESS WIRE)--ZIPS Car Wash is launching its summer “Red, White & Shine” celebration, a seasonal promotion during peak summer travel, including road trips, lake visits, and all those celebrating America’s 250th Anniversary. ZIPS is offering customers 25% off the Best Wash package at participating locations nationwide. The limited time offer runs from June 23–July 12, 2026, using promo code USA. “We want to help Americans keep their vehicles clean and protected through every...

LONDON--(BUSINESS WIRE)--  24-June-2026 Issue: Mitsubishi HC Capital UK Plc Series 881 XS2901976279 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 27-March-2026 Date To: 29-June-2026 Record Date: 24-June-2026 Value Date: 29-June-2026 Benchmark Rate: 0.74108% Margin: 0.46% Total Rate: 1.20108% Floor: 0% Number of Days: 94 Day Count: Actual / 365 (Fixed) Interest Frequency: Quarterly Total Amount Due: JPY...

AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an in...

NEW YORK--(BUSINESS WIRE)--OXIO, the leading Telecom-as-a-Service (TaaS) platform, today announced the launch of Advanced Core Routing (ACR), a network-native capability that gives enterprises and brands real-time, bi-directional control over mobile voice and messaging traffic through OXIO’s telecom ecosystem. A native-intercept layer built into OXIO’s cloud-native telecom core, ACR enables organizations to prevent fraud, provide custom, real-time routing and decisioning, strengthen subscriber...

CHESAPEAKE, Va.--(BUSINESS WIRE)--Dollar Tree, Inc. (NASDAQ: DLTR) (the “Company” or “Dollar Tree”) today announced that certain funds affiliated with Mantle Ridge LP (“Mantle Ridge”) and a selling stockholder that is counterparty to derivative agreements with affiliates of Mantle Ridge (collectively, the “Selling Stockholders”) have launched a secondary block trade (the “block trade”) to sell 12,820,400 shares of the Company’s common stock (the “common stock”) to J.P. Morgan and Goldman Sachs...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. “We are pleased to welcome Jay to Insulet’s Board of Directors,” said President and CEO Ashley McEvoy. “Jay has a strong track record of...

WASHINGTON--(BUSINESS WIRE)--REPUBLICAN VOTERS SEND A CLEAR MESSAGE TO WASHINGTON: PROTECT ACCESS TO EMERGENCY CONTRACEPTION...

NEW YORK--(BUSINESS WIRE)--FlightHub, a leading North American online travel agency, is expanding its travel ecosystem with the launch of FlightHub Hotels, which will allow travelers to book flights, hotels, and bundled travel packages in one place. The new offering gives travelers access to more than 2.6 million accommodation options worldwide, marking a significant step in FlightHub’s evolution as a one-stop shop for travel planning.To celebrate the launch, FlightHub is introducing a limited-t...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos’ proprietary iLution platform, a novel ophthalmic drug-delivery syste...